{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:08Z","timestamp":1793398208283,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"2026 Hebei Provincial Government Funded Project for Outstanding Clinical Medical Talents","award":["ZF2026163"],"award-info":[{"award-number":["ZF2026163"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10620-026-10076-8","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:36:13Z","timestamp":1782286573000},"page":"5049-5062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["IL-17\/IL-17RA Axis Facilitates Immune Evasion in Hepatocellular Carcinoma by Upregulating PD-L1 via the NF-\u03baB Pathway"],"prefix":"10.1007","volume":"71","author":[{"given":"Xinyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-4641","authenticated-orcid":false,"given":"Caiyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"10076_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G et al. Hepatocellular carcinoma. Lancet. 2022;400:1345\u20131362. https:\/\/doi.org\/10.1016\/S0140-6736(22)01200-4.","journal-title":"Lancet."},{"key":"10076_CR2","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1053\/j.gastro.2018.09.051","volume":"156","author":"TF Greten","year":"2019","unstructured":"Greten TF, Lai CW, Li G et al. Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology. 2019;156:510\u2013524. https:\/\/doi.org\/10.1053\/j.gastro.2018.09.051.","journal-title":"Gastroenterology."},{"key":"10076_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101130","volume":"6","author":"A Childs","year":"2024","unstructured":"Childs A, Aidoo-Micah G, Maini MK et al. Immunotherapy for hepatocellular carcinoma. JHEP Rep. 2024;6:101130. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101130.","journal-title":"JHEP Rep."},{"key":"10076_CR4","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/hep.32740","volume":"77","author":"R Donne","year":"2023","unstructured":"Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77:1773\u20131796. https:\/\/doi.org\/10.1002\/hep.32740.","journal-title":"Hepatology."},{"key":"10076_CR5","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/cac2.12345","volume":"42","author":"K Cheng","year":"2022","unstructured":"Cheng K, Cai N, Zhu J et al. Tumor-associated macrophages in liver cancer: from mechanisms to therapy. Cancer Commun (Lond). 2022;42:1112\u20131140. https:\/\/doi.org\/10.1002\/cac2.12345.","journal-title":"Cancer Commun (Lond)."},{"key":"10076_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103806","volume":"24","author":"L Yang","year":"2025","unstructured":"Yang L, Zheng SG. Role of regulatory T cells in inflammatory liver diseases. Autoimmun Rev. 2025;24:103806. https:\/\/doi.org\/10.1016\/j.autrev.2025.103806.","journal-title":"Autoimmun Rev."},{"key":"10076_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang X, Wang J, Lu D et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther. 2021;6:75. https:\/\/doi.org\/10.1038\/s41392-021-00484-9.","journal-title":"Signal Transduct Target Ther."},{"key":"10076_CR8","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.3390\/ijms22136995","volume":"22","author":"AJ Boutilier","year":"2021","unstructured":"Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22:6995. https:\/\/doi.org\/10.3390\/ijms22136995.","journal-title":"Int J Mol Sci."},{"key":"10076_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104997","volume":"216","author":"K Rahi","year":"2025","unstructured":"Rahi K, Hedayati M, Hendi Z et al. Liver microenvironment and therapy resistance in hepatocellular carcinoma. Crit Rev Oncol Hematol. 2025;216:104997. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104997.","journal-title":"Crit Rev Oncol Hematol."},{"key":"10076_CR10","doi-asserted-by":"publisher","first-page":"15539","DOI":"10.3390\/ijms241713539","volume":"24","author":"Z Chen","year":"2023","unstructured":"Chen Z, Qiao S, Yang L et al. Mechanistic insights into the roles of the IL-17\/IL-17R families in pancreatic cancer. Int J Mol Sci. 2023;24:15539. https:\/\/doi.org\/10.3390\/ijms241713539.","journal-title":"Int J Mol Sci."},{"key":"10076_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1055\/s-0041-1730926","volume":"41","author":"N Li","year":"2021","unstructured":"Li N, Yamamoto G, Fuji H et al. Interleukin-17 in liver disease pathogenesis. Semin Liver Dis. 2021;41:507\u2013515. https:\/\/doi.org\/10.1055\/s-0041-1730926.","journal-title":"Semin Liver Dis."},{"key":"10076_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687975","volume":"12","author":"D Zeng","year":"2021","unstructured":"Zeng D, Ye Z, Shen R et al. IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front Immunol. 2021;12:687975. https:\/\/doi.org\/10.3389\/fimmu.2021.687975.","journal-title":"Front Immunol."},{"key":"10076_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202518487","volume":"12","author":"J Lan","year":"2025","unstructured":"Lan J, Li H, Xue J et al. The immune microenvironment in liver cancer: from analysis to targeting. Adv Sci (Weinh). 2025;12:e18487. https:\/\/doi.org\/10.1002\/advs.202518487.","journal-title":"Adv Sci (Weinh)."},{"key":"10076_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13046-025-03490-9","volume":"44","author":"F Liu","year":"2025","unstructured":"Liu F, Li X, Zhang Y et al. Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma. J Exp Clin Cancer Res. 2025;44:227. https:\/\/doi.org\/10.1186\/s13046-025-03490-9.","journal-title":"J Exp Clin Cancer Res."},{"key":"10076_CR15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41419-024-06888-z","volume":"15","author":"D Li","year":"2024","unstructured":"Li D, Zhang T, Guo Y et al. Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma. Cell Death Dis. 2024;15:498. https:\/\/doi.org\/10.1038\/s41419-024-06888-z.","journal-title":"Cell Death Dis."},{"key":"10076_CR16","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1158\/1535-7163.Mct-23-0660","volume":"23","author":"YT Liu","year":"2024","unstructured":"Liu YT, Mao ZW, Ding Y et al. Macrophages as targets in hepatocellular carcinoma therapy. Mol Cancer Ther. 2024;23:780\u2013790. https:\/\/doi.org\/10.1158\/1535-7163.Mct-23-0660.","journal-title":"Mol Cancer Ther."},{"key":"10076_CR17","doi-asserted-by":"publisher","first-page":"1431211","DOI":"10.3389\/fimmu.2024.1431211","volume":"15","author":"G Du","year":"2024","unstructured":"Du G, Dou C, Sun P et al. Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy. Front Immunol. 2024;15:1431211. https:\/\/doi.org\/10.3389\/fimmu.2024.1431211.","journal-title":"Front Immunol."},{"key":"10076_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104195","volume":"357","author":"D Osei-Bordom","year":"2020","unstructured":"Osei-Bordom D, Bozward AG, Oo YH. The hepatic microenvironment and regulatory T cells. Cell Immunol. 2020;357:104195. https:\/\/doi.org\/10.1016\/j.cellimm.2020.104195.","journal-title":"Cell Immunol."},{"key":"10076_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/15384101.2025.2583289","volume":"24","author":"M Ghasemian-Irani","year":"2025","unstructured":"Ghasemian-Irani M, Babaei S, Kazemi T. Exosomes in hepatocellular carcinoma: involvement in reprogramming the tumor microenvironment for immune evasion, metastasis, angiogenesis, and drug resistance. Cell Cycle. 2025;24:529\u2013551. https:\/\/doi.org\/10.1080\/15384101.2025.2583289.","journal-title":"Cell Cycle."},{"key":"10076_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115013","volume":"161","author":"S Pu","year":"2025","unstructured":"Pu S, Liu T, Gao Y et al. The role of tumor-associated endothelial cells in malignant progression and immune evasion of liver cancer. Int Immunopharmacol. 2025;161:115013. https:\/\/doi.org\/10.1016\/j.intimp.2025.115013.","journal-title":"Int Immunopharmacol."},{"key":"10076_CR21","doi-asserted-by":"publisher","first-page":"1592837","DOI":"10.3389\/fimmu.2025.1592837","volume":"16","author":"B Gao","year":"2025","unstructured":"Gao B, Lu Y, Lai X et al. Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications. Front Immunol. 2025;16:1592837. https:\/\/doi.org\/10.3389\/fimmu.2025.1592837.","journal-title":"Front Immunol."},{"key":"10076_CR22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/s41423-025-01308-4","volume":"22","author":"D Seyhan","year":"2025","unstructured":"Seyhan D, Allaire M, Fu Y et al. Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy. Cell Mol Immunol. 2025;22:1132\u20131158. https:\/\/doi.org\/10.1038\/s41423-025-01308-4.","journal-title":"Cell Mol Immunol."},{"key":"10076_CR23","doi-asserted-by":"publisher","first-page":"1408710","DOI":"10.3389\/fimmu.2024.1408710","volume":"15","author":"WC Theune","year":"2024","unstructured":"Theune WC, Chen J, Theune EV et al. Interleukin-17 directly stimulates tumor infiltrating Tregs to prevent cancer development. Front Immunol. 2024;15:1408710. https:\/\/doi.org\/10.3389\/fimmu.2024.1408710.","journal-title":"Front Immunol."},{"key":"10076_CR24","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1158\/1078-0432.Ccr-16-0617","volume":"23","author":"TJ Li","year":"2017","unstructured":"Li TJ, Jiang YM, Hu YF et al. Interleukin-17-producing neutrophils link inflammatory stimuli to disease progression by promoting angiogenesis in gastric cancer. Clin Cancer Res. 2017;23:1575\u20131585. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0617.","journal-title":"Clin Cancer Res."},{"key":"10076_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110757","volume":"123","author":"M Song","year":"2023","unstructured":"Song M, Liang J, Wang L et al. IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment. Int Immunopharmacol. 2023;123:110757. https:\/\/doi.org\/10.1016\/j.intimp.2023.110757.","journal-title":"Int Immunopharmacol."},{"key":"10076_CR26","doi-asserted-by":"publisher","first-page":"1671288","DOI":"10.3389\/fimmu.2025.1671288","volume":"16","author":"G Konstantis","year":"2025","unstructured":"Konstantis G, Passenberg M, Guntlisbergen C et al. Serum IL-17F as a biomarker of infection-independent cirrhosis progression. Front Immunol. 2025;16:1671288. https:\/\/doi.org\/10.3389\/fimmu.2025.1671288.","journal-title":"Front Immunol."},{"key":"10076_CR27","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.2147\/jir.S452061","volume":"17","author":"X Yang","year":"2024","unstructured":"Yang X, Liao L, Liang Z et al. Correlation analysis of IL-17, IL-21, IL-23 with non-alcoholic liver fibrosis and cirrhosis. J Inflamm Res. 2024;17:2327\u20132335. https:\/\/doi.org\/10.2147\/jir.S452061.","journal-title":"J Inflamm Res."},{"key":"10076_CR28","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.4103\/nrr.Nrr-d-25-00026","volume":"21","author":"G Deng","year":"2026","unstructured":"Deng G, Guo M, Fan J et al. Interleukin-17 family in health and immune diseases: from origin to clinical implications. Neural Regen Res. 2026;21:1809\u20131833. https:\/\/doi.org\/10.4103\/nrr.Nrr-d-25-00026.","journal-title":"Neural Regen Res."},{"key":"10076_CR29","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1038\/s41388-024-03169-z","volume":"43","author":"G Lin","year":"2024","unstructured":"Lin G, Tian F, Yu Q et al. IL-17RA\/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer growth. Oncogene. 2024;43:3598\u20133616. https:\/\/doi.org\/10.1038\/s41388-024-03169-z.","journal-title":"Oncogene."},{"key":"10076_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.70047","volume":"39","author":"F Gao","year":"2025","unstructured":"Gao F, Chen X, Li X et al. The pro-migratory and pro-invasive roles of cancer-associated fibroblasts secreted IL-17A in prostate cancer. J Biochem Mol Toxicol. 2025;39:e70047. https:\/\/doi.org\/10.1002\/jbt.70047.","journal-title":"J Biochem Mol Toxicol."},{"key":"10076_CR31","doi-asserted-by":"publisher","DOI":"10.71321\/tg620c27","volume":"1","author":"G Zhou","year":"2025","unstructured":"Zhou G, Li A, Wang R. The role of IL-17 family in the process of pulmonary fibrosis. Life Conflux. 2025;1:e217. https:\/\/doi.org\/10.71321\/tg620c27.","journal-title":"Life Conflux."},{"key":"10076_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2025.01.002","volume":"83","author":"A Saran","year":"2025","unstructured":"Saran A, Nishizaki D, Lippman SM et al. Interleukin-17: a pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders. Cytokine Growth Factor Rev. 2025;83:35\u201344. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.01.002.","journal-title":"Cytokine Growth Factor Rev."},{"key":"10076_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104999","volume":"217","author":"S Wang","year":"2025","unstructured":"Wang S, Wang J, Wu S et al. The central role of IL-17 in cancer stemness and immune evasion: a novel axis for overcoming immune checkpoint inhibitor resistance. Crit Rev Oncol Hematol. 2025;217:104999. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104999.","journal-title":"Crit Rev Oncol Hematol."},{"key":"10076_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7059","volume":"13","author":"JK Jiang","year":"2024","unstructured":"Jiang JK, Lin CH, Chang TA et al. Decreased interleukin-17RA expression is associated with good prognosis in patients with colorectal cancer and inhibits tumor growth and vascularity in mice. Cancer Med. 2024;13:e7059. https:\/\/doi.org\/10.1002\/cam4.7059.","journal-title":"Cancer Med."},{"key":"10076_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70493","volume":"15","author":"Y Hao","year":"2025","unstructured":"Hao Y, Wang S, Wang J et al. Reprogrammed MDSCs promote Th1-dominant antitumour response via CD40 induced by autocrine TNF-\u03b1 after combining cryo-thermal therapy with IL6 and IL17A neutralization. Clin Transl Med. 2025;15:e70493. https:\/\/doi.org\/10.1002\/ctm2.70493.","journal-title":"Clin Transl Med."},{"key":"10076_CR36","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.7150\/ijbs.86767","volume":"19","author":"W Jia","year":"2023","unstructured":"Jia W, Liang S, Lin W et al. Hypoxia-induced exosomes facilitate lung pre-metastatic niche formation in hepatocellular carcinoma through the miR-4508-RFX1-IL17A-p38 MAPK-NF-\u03baB pathway. Int J Biol Sci. 2023;19:4744\u20134762. https:\/\/doi.org\/10.7150\/ijbs.86767.","journal-title":"Int J Biol Sci."},{"key":"10076_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.03.014","volume":"11","author":"H Deng","year":"2024","unstructured":"Deng H, Liu Q, Yu S et al. Narciclasine induces colon carcinoma cell apoptosis by inhibiting the IL-17A\/Act1\/TRAF6\/NF-\u03baB signaling pathway. Genes Dis. 2024;11:100938. https:\/\/doi.org\/10.1016\/j.gendis.2023.03.014.","journal-title":"Genes Dis."},{"key":"10076_CR38","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1007\/s12672-025-03945-7","volume":"16","author":"Y Wei","year":"2025","unstructured":"Wei Y, Chu Y, Wang S et al. Prolonged neoadjuvant hormonal therapy enhances IL-17 A\/STAT3-mediated inflammation in prostate cancer. Discov Oncol. 2025;16:2102. https:\/\/doi.org\/10.1007\/s12672-025-03945-7.","journal-title":"Discov Oncol."},{"key":"10076_CR39","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.bbrc.2019.11.134","volume":"522","author":"J Li","year":"2020","unstructured":"Li J, Zeng M, Yan K et al. IL-17 promotes hepatocellular carcinoma through inhibiting apoptosis induced by IFN-\u03b3. Biochem Biophys Res Commun. 2020;522:525\u2013531. https:\/\/doi.org\/10.1016\/j.bbrc.2019.11.134.","journal-title":"Biochem Biophys Res Commun."},{"key":"10076_CR40","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.jhep.2019.08.034","volume":"71","author":"Y Wei","year":"2019","unstructured":"Wei Y, Shi D, Liang Z et al. IL-17A secreted from lymphatic endothelial cells promotes tumorigenesis by upregulation of PD-L1 in hepatoma stem cells. J Hepatol. 2019;71:1206\u20131215. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.034.","journal-title":"J Hepatol."},{"key":"10076_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001895","volume":"9","author":"C Liu","year":"2021","unstructured":"Liu C, Liu R, Wang B et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021;9:e001895. https:\/\/doi.org\/10.1136\/jitc-2020-001895.","journal-title":"J Immunother Cancer."},{"key":"10076_CR42","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1186\/s12967-023-04365-3","volume":"21","author":"H Liao","year":"2023","unstructured":"Liao H, Chang X, Gao L et al. IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer. J Transl Med. 2023;21:828. https:\/\/doi.org\/10.1186\/s12967-023-04365-3.","journal-title":"J Transl Med."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10076-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10076-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10076-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:03:16Z","timestamp":1789052596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10076-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10076"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10076-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Ethics Committee of the Hebei Medical University Third Hospital (No. 2024-012-1) and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}